Vaccine Supply Update

Advisory Committee on Immunization Practices

Atlanta, GA
June 21, 2018

Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
Outline

- Hepatitis A Supply Update
- Hepatitis B Supply Update
  - Adult
  - Pediatric
- CDC Vaccine Supply/Shortage Page
Adult Hepatitis A Vaccine

- During 2017, large outbreaks of hepatitis A among adults in several US cities resulted in increased demand for vaccine and constrained supply.

- Actions taken included collaboration between CDC and public health officials in affected jurisdictions to target vaccine based on local epidemiology; implementation of ordering controls to maintain an equitable distribution of vaccine in unaffected jurisdictions; and modification of CDC’s vaccine contracts to support additional vaccine purchase.

- In addition, both GSK and Merck have increased the amount of vaccine available in the US market for outbreaks and routine use.
Adult Hepatitis A Vaccine, II

- Vaccine continues to be directed toward jurisdictions with outbreaks. In addition, as vaccine supplies have improved, the vaccine supply strategy has evolved, making more vaccine available for routine use and/or prevention activities in jurisdictions without large, ongoing outbreaks.

- CDC and vaccine manufacturers are continuing to monitor ongoing demand for and usage of adult hepatitis A vaccine closely.
Merck is not currently distributing its adult hepatitis B vaccine or dialysis formulation and will not be distributing vaccine through the end of 2018.

GSK has sufficient supply of adult hepatitis B vaccine to address the anticipated gap in Merck’s adult hepatitis B vaccine supply during this period; however, preferences for a specific presentation (i.e., vial versus syringe) may not be met uniformly during this time.
Pediatric Hepatitis B Vaccine

- Merck has not been distributing its pediatric hepatitis B vaccines since mid-2017 and will continue to have a limited supply of pediatric hepatitis B vaccine during 2018.

- Together, both manufacturers (Merck and GSK) are able to supply the US market with approximately 10% less monovalent pediatric hepatitis B vaccine than normal during 2018.

- This expected monovalent supply is sufficient to cover the birth dose for all children as well as additional vaccine for some second and third doses.
Pediatric Hepatitis B Vaccine, II

- CDC has implemented controlled vaccine ordering in the public sector using both Merck’s and GSK’s monovalent vaccines.

- In addition, GSK is providing monovalent vaccine to the private sector aligned with CDC’s clinical guidance.

- GSK’s DTaP-HepB-IPV combination vaccine (Pediarix) continues to be available in the public and private sectors.
CDC’s Vaccine Supply/Shortage Webpage

- Available at: https://www.cdc.gov/vaccines/hcp/clinical-resources/shortages.html